SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study.
Adult
Antibodies, Viral
/ blood
COVID-19
/ epidemiology
Female
Germany
/ epidemiology
Humans
Immunoglobulin G
/ blood
Liver Transplantation
/ adverse effects
Male
Middle Aged
Postoperative Complications
/ epidemiology
Prospective Studies
RNA, Viral
/ blood
Risk Factors
SARS-CoV-2
/ immunology
Seroconversion
Seroepidemiologic Studies
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
16
11
2020
accepted:
17
11
2020
pubmed:
17
1
2021
medline:
3
7
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
In liver transplant (LT) recipients with severe coronavirus disease 2019 (COVID-19), fatal outcome has been reported in a substantial subset of patients. Whether LT recipients are at increased risk for severe COVID-19 compared with the general population is controversial. Here we report the results of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in a large LT recipient cohort. A total of 219 LT recipients were enrolled between May 5, 2020, and August 6, 2020, at the University Hospital Heidelberg. Serum blood samples were collected and tested for anti-SARS-CoV-2 IgG. SARS-CoV-2 RNA was detected in nasopharyngeal swabs using reverse transcription-polymerase chain reaction assays. Taking into account known risk factors of arterial hypertension, obesity, diabetes, or leukopenia, LT recipients a priori represented a high-risk cohort for severe COVID-19 with 101 of 219 (46.1%) presenting with more than 2 risk factors for severe COVID-19. Out of 219 LT recipients, 8 (3.7%) either had a positive test result for nasopharyngeal SARS-CoV-2 RNA or anti-SARS-CoV-2 serum IgG. Five of eight (62.5%) did not show any clinical signs of infection, three of eight (37.5%) had self-limited disease, and none required hospitalization for COVID-19. Two of eight (25%) had known exposure to infected health care staff as the probable source of infection. In summary, LT recipients showed a SARS-CoV-2 seroconversion rate similar to that of the general population with a substantial percentage of unrecognized infections.
Sections du résumé
BACKGROUND
BACKGROUND
In liver transplant (LT) recipients with severe coronavirus disease 2019 (COVID-19), fatal outcome has been reported in a substantial subset of patients. Whether LT recipients are at increased risk for severe COVID-19 compared with the general population is controversial. Here we report the results of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in a large LT recipient cohort.
METHODS
METHODS
A total of 219 LT recipients were enrolled between May 5, 2020, and August 6, 2020, at the University Hospital Heidelberg. Serum blood samples were collected and tested for anti-SARS-CoV-2 IgG. SARS-CoV-2 RNA was detected in nasopharyngeal swabs using reverse transcription-polymerase chain reaction assays.
RESULTS
RESULTS
Taking into account known risk factors of arterial hypertension, obesity, diabetes, or leukopenia, LT recipients a priori represented a high-risk cohort for severe COVID-19 with 101 of 219 (46.1%) presenting with more than 2 risk factors for severe COVID-19. Out of 219 LT recipients, 8 (3.7%) either had a positive test result for nasopharyngeal SARS-CoV-2 RNA or anti-SARS-CoV-2 serum IgG. Five of eight (62.5%) did not show any clinical signs of infection, three of eight (37.5%) had self-limited disease, and none required hospitalization for COVID-19. Two of eight (25%) had known exposure to infected health care staff as the probable source of infection.
CONCLUSIONS
CONCLUSIONS
In summary, LT recipients showed a SARS-CoV-2 seroconversion rate similar to that of the general population with a substantial percentage of unrecognized infections.
Identifiants
pubmed: 33451759
pii: S0041-1345(20)32904-3
doi: 10.1016/j.transproceed.2020.11.009
pmc: PMC7831557
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1112-1117Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Am J Transplant. 2020 Jul;20(7):1826-1836
pubmed: 32323460
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016
pubmed: 32866433
Am J Transplant. 2020 Oct;20(10):2876-2882
pubmed: 32412159
Transpl Infect Dis. 2020 Dec;22(6):e13363
pubmed: 32516847
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243353
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Circulation. 2020 Jul 7;142(1):4-6
pubmed: 32320270
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Gut. 2020 Oct;69(10):1832-1840
pubmed: 32571972
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):643-644
pubmed: 32339474
Transpl Infect Dis. 2021 Feb;23(1):e13417
pubmed: 32666588
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343